The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024A Novel Brain-penetrating Antibody for Treating Parkinson’s Disease
Study Rationale: Inflammation in the brain is an important trigger of Parkinson’s disease (PD). Our strategy is to block one of the key molecules mediating inflammation and degeneration in the brain...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Biomarker Development and IND-Enabling Toxicology Support for Novel, Small Molecules that Enhance Lysosomal Function for the Treatment of Parkinson’s Disease
Study Rationale: In people with Parkinson’s disease (PD), neurons exhibit decreased ability to remove cellular trash. This dysfunction is caused by a reduction in the number and effectiveness of the...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Targeting Lipid Biology in Stem Cell-derived Neurons to Develop a New Therapeutic Drug for Parkinson’s Disease
Study Rationale: Neurons derived from the stem cells of people with Parkinson’s disease (PD) offer an excellent vehicle for identifying potentially disease-modifying therapeutic compounds. We...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Development of a First-in-class Inhibitor of the “Mitochondrial Permeability Transition Pore” as a Novel Disease-modifying Treatment for Parkinson’s Disease
Study Rationale: Mitochondria are subcellular structures that produce energy and help regulate the movement of calcium ions that continually flow into brain cells when they are active, ions that can...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Development of Brain-penetrant TrkB Agonist Antibody for Parkinson’s Disease
Study Rationale: Parkinson's disease (PD) is characterized by the death of dopamine neurons, which control movement. We have generated a novel therapeutic agent — an antibody that activates a receptor...
-
Research Grant, 2024Quantification of Three Previously Identified Biomarkers of Progression in Stage 2/3 of Parkinson’s Disease
Study Rationale: Early indicators for Parkinson’s disease (PD), so-called biomarkers, are needed to identify subjects at risk during the earliest, prodromal stages of disease and to support clinical...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.